###### Strengths and limitations of this study

-   The strengths of our study are its population-based design, use of a single administrative database analysis with the National Health Insurance Research Database records, and generalisability of findings with a very large sample size including study and control cohorts.

-   The association between Hashimoto's thyroiditis (HT) and cholelithiasis, either symptomatic or asymptomatic, as well as between HT and cholecystectomy, was assessed to validate the aforementioned association and to diminish the possibility of surveillance bias.

-   The retrospective cohort study is subject to many biases related to the necessary adjustments for confounding factors.

-   The evidence derived from a retrospective cohort study is generally of lower methodological quality than that from randomised trials, and the causal relationship of HT to cholelithiasis and cholecystectomy could not be ascertained in this study.

Introduction {#s1}
============

Cholelithiasis involves gallbladder stones, intrahepatic stones (IHS) and common bile duct (CBD) stones. Among the subtypes of cholelithiasis, the reported proportion of gallbladder stones was approximately 85%, that of CBD stones was 19% and that of IHS was 11%--15%.[@R1] The prevalence of cholelithiasis varies with ethnicity, environment, lifestyle and dietary habits. The reported prevalence of cholelithiasis in the USA ranged between 10% and 12%, whereas that in Taiwan ranged between 5% and 10%.[@R4] Of individuals with gallbladder stones, 20% were reported to experience biliary symptoms in their lifetime, and approximately 1%--2% of patients with gallbladder stones require surgery annually.[@R7] Nearly 10%--15% of patients with CBD stones were reported to harbour concomitant gallbladder stones, which were considered to be the origin of stone migration, and the remaining patients (85%--90%) were considered to present de novo stones in the CBD.[@R8] Approximately 10% of patients with CBD stones remained asymptomatic; however, only 2% of patients with CBD stones exhibited no signs of elevated liver function tests, dilated CBD, jaundice or pancreatitis.[@R9] Therefore, the extraction of CBD stones is recommended if possible, regardless of whether they are symptomatic.[@R10] More than 50% of patients with IHS experience suppurative cholangitis or cholangiocarcinoma if the stones are not completely retrieved.[@R11] In brief, cholelithiasis is one of the common morbidities among the adult population, and it is a major public health concern because of its potential development to cholecystitis, cholangitis, pancreatitis and biliary tract cancers.

Hashimoto's thyroiditis (HT) often leads to hypothyroidism, resulting from chronic destruction of the thyroid gland by an autoimmune process.[@R12] The reported prevalence of HT in Western countries was approximately 0.1%--5%, and women exhibited a 10-fold to 20-fold higher risk of harbouring HT.[@R13] The diagnosis of HT is mainly based on the presence of circulating antibodies to thyroperoxidase or thyroglobulin, reduced echogenicity on thyroid ultrasound, and manifestations of compression of organs adjacent to the thyroid gland. The utilisation of radioactive iodine or cytological examinations of thyroid aspirate was rarely applied in clinical practice.[@R14] Moreover, HT was more prevalent in middle-aged individuals (between 45 and 65 years). HT is reported to be both the most common endocrine disorder and the most common cause of hypothyroidism.[@R14]

Hypothyroidism is a well-known risk factor for cholelithiasis, particularly for gallstone diseases (GSD). However, not all patients will develop hypothyroidism, and they sometimes present euthyroid or hyperthyroid features.[@R15] It has been reported that either euthyroidism or subclinical hypothyroidism in children with HT frequently evolved towards clinical hypothyroidism, whereas those presenting with overt hyperthyroidism always had definitive resolution of hyperthyroid to evolve towards euthyroidism or hypothyroidism.[@R16] Furthermore, the association between HT and cholelithiasis has never been discussed in the literature. In this study, we hypothesised that HT per se is associated with an increased risk of cholelithiasis. We conducted a nationwide population-based cohort study by analysing data from the Longitudinal Health Insurance Research Database (LHID2000) of the Taiwan National Health Insurance Research Database (NHIRD) to determine the association between HT and the subsequent development of cholelithiasis, either symptomatic or asymptomatic, in considering the confounding factors of hypothyroidism and hyperthyroidism. Furthermore, we also assessed the association between HT and cholecystectomy to diminish surveillance bias and to validate the aforementioned association between HT and cholelithiasis.

Methods {#s2}
=======

Data source {#s2a}
-----------

This was a nationwide cohort study using the LHID2000 of the NHIRD, which contains claims data of the beneficiaries of the National Health Insurance (NHI) programme in Taiwan.[@R18] In brief, this NHI programme began on 1 March 1995, and covers approximately 99% of the 23.74 million residents of Taiwan. The details of the NHI programme and LHID2000 have been thoroughly addressed in previous studies.[@R19] Diseases were coded according to the 2001 International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

Patient and public involvement statement {#s2b}
----------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the selection process of the participants in the two study cohorts. This study recruited patients with newly diagnosed HT (ICD-9 code 245.2) who were aged ≥20 years from LHID2000 between 1 January 2000 and 31 December 2010. The date of diagnosis of HT was defined as the index date. The control cohort was randomly selected from LHID2000 and included patients without a history of HT who were propensity-matched with the case cohort at a ratio of 4:1. Non-HT control patients were frequency-matched with respect to age group (every 5-year span); sex; comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, chronic obstructive pulmonary disease (COPD), obesity, stroke, coronary artery disease (CAD), hepatitis B virus, hepatitis C virus and inflammatory bowel disease (IBD); and index year of HT diagnosis. The index date for control patients was randomly appointed based on the month and day with the same index year of the matched patients. We also considered hyperthyroidism and hypothyroidism as comorbidities. Patients with a history of cholelithiasis (ICD-9-CM code 574) and those with incomplete information on age or sex at baseline were excluded from both the HT and non-HT cohorts. Each patient was examined from the index date until the occurrence of cholelithiasis, death, withdrawal from the NHI programme or the end of 31 December 2011. Individuals who emigrated out of Taiwan or who died are withdrawn from the NIH programme. Both identified cause-specific and non-cause-specific deaths were included in the analysis, whereas deaths were censored if the cause could not be identified.

![Selection process of the participants in the two study cohorts.](bmjopen-2017-020798f01){#F1}

Statistical analysis {#s2c}
--------------------

The distributions of age, sex and comorbidities between the HT and non-HT cohorts were compared and examined using the χ^2^ test. The mean ages (SDs) and mean follow-up period (SDs) between the cohorts were compared and tested using Student's t-test. The Kaplan-Meier method was used to compare the cumulative incidence of cholelithiasis events and survival between the cohorts, and the log-rank test was used to examine the differences. Cholelithiasis incidence density rates were estimated by dividing the number of cholelithiasis events by the number of person-years for each risk factor, and the results were then stratified by age, sex, and presence or absence of a comorbidity. Univariable and multivariable Cox proportional hazard regression models were used to assess the risk of cholelithiasis associated with HT. The HRs and 95% CIs were estimated using the Cox model, which were adjusted for age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, COPD, CAD, IBD, hyperthyroidism and hypothyroidism. Multivariable Cox proportional hazard regression models were also used to assess the association between cholecystectomy and HT. All data analyses were performed using SAS V.9.4. The significance level was set at two-tailed p\<0.05.

Results {#s3}
=======

The study examined an HT cohort of 1268 patients and a non-HT cohort of 5021 patients ([table 1](#T1){ref-type="table"}). The HT and non-HT cohorts were well matched for age, sex and comorbidities. The mean ages in the HT and non-HT cohorts were 42.7±13.6 and 42.4±13.8 years, respectively. Most patients were older than 35 years (65.5%) and were women (90.0%). Excluding hyperthyroidism and hypothyroidism, the top three common comorbidities according to the order of frequency in these study cohorts were hypertension (18.0%), hyperlipidaemia (17.8%) and CAD (10.8%). It was noted that hyperthyroidism and hypothyroidism were more prevalent in the HT cohort than in the non-HT cohort. Of the 367 patients of the HT cohort with a history of hyperthyroidism, 171 (46.6%) patients had history of Graves' disease (GD) before evolving to HT. Of the 96 patients of non-HT cohort with a history of hyperthyroidism, 41 (42.7%) patients had history of GD.

###### 

Demographic characteristics and comorbidities of cohorts with and without Hashimoto's thyroiditis

  Variable                                 Hashimoto's thyroiditis   P values      
  ---------------------------------------- ------------------------- ------------- ---------
  Age, year                                                                        0.98
   ≤34                                     1743 (34.7)               437 (34.5)    
   35--49                                  1886 (37.6)               476 (37.5)    
   50+                                     1392 (27.7)               355 (28.0)    
   Mean±SD\*                               42.4 (13.8)               42.7 (13.6)   0.57
  Sex                                                                              0.97
   Female                                  4520 (90.0)               1141 (90.0)   
   Male                                    501 (9.98)                127 (10.0)    
  Comorbidity                                                                      
   Hyperlipidaemia                         881 (17.6)                226 (17.8)    0.82
   Diabetes                                302 (6.01)                80 (6.31)     0.69
   Liver cirrhosis                         22 (0.44)                 9 (0.71)      0.22
   Alcohol-related illness                 98 (1.95)                 30 (2.37)     0.35
   Hypertension                            886 (17.7)                228 (18.0)    0.78
   Chronic obstructive pulmonary disease   379 (7.55)                102 (8.04)    0.55
   Obesity                                 166 (3.31)                44 (3.47)     0.77
   Stroke                                  44 (0.88)                 14 (1.10)     0.45
   Coronary artery disease                 524 (10.4)                137 (10.8)    0.70
   Hepatitis B virus                       183 (3.64)                49 (3.86)     0.71
   Hepatitis C virus                       69 (1.37)                 20 (1.58)     0.58
   Inflammatory bowel disease              26 (0.52)                 9 (0.71)      0.41
   Hyperthyroidism                         96 (1.91)                 367 (28.9)    \<0.001
   Hypothyroidism                          26 (0.52)                 277 (21.9)    \<0.001

χ^2^ test.

\*t-test.

[Figure 2](#F2){ref-type="fig"} shows the cumulative incidences (100%) of cholelithiasis in the HT and the non-HT cohorts during the follow-up period. The cumulative incidence of cholelithiasis was higher in the HT cohort than that in the non-HT cohort (log-rank test, p\<0.001). The average follow-up duration was 5.91±3.24 years for the HT cohort and 5.88±3.22 years for the non-HT cohort.

![Cumulative incidences (100%) of cholelithiasis in the HT and the non-HT cohorts. HT, Hashimoto's thyroiditis.](bmjopen-2017-020798f02){#F2}

[Table 2](#T2){ref-type="table"} presents the incidence of and risk factors for cholelithiasis. The overall incidence density rates of cholelithiasis in the HT and non-HT cohorts were 3.74 and 2.24 per 1000 person-years, respectively. Compared with patients without HT, those with HT were associated with an increased risk of cholelithiasis (adjusted HR (aHR)=1.91, 95% CI 1.58 to 2.33) after adjustment for age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, COPD, CAD, IBD, hyperthyroidism and hypothyroidism. HT was found to be consistently associated with the development of cholelithiasis (aHR=1.96, 95% CI 1.60 to 2.40) after we excluded the 171 patients with a history of GD before evolving to HT to avoid enrolling a more varied autoimmune thyroid disease group into the HT cohort (data not shown). Compared with patients aged ≤34 years, the risk of cholelithiasis was 2.14-fold higher in those aged 35--49 years (95% CI 1.67 to 2.75) and 4.33-fold higher in those aged ≥50 years (95% CI 3.33 to 5.64). Multivariable analysis for comorbidities revealed that hyperlipidaemia (aHR=1.39, 95% CI 1.15 to 1.68), diabetes (aHR=1.55, 95% CI 1.22 to 1.97), liver cirrhosis (aHR=2.27, 95% CI 1.07 to 4.85), CAD (aHR=2.04, 95% CI 1.67 to 2.50) and IBD (aHR=3.21, 95% CI 1.87 to 5.52) remained the independent risk factors for cholelithiasis.

###### 

Incidence and risk factors for cholelithiasis

  Variable                   Event   Person-years   Rate†   Crude HR (95% CI)           Adjusted HR‡ (95% CI)
  -------------------------- ------- -------------- ------- --------------------------- ----------------------------
  Hashimoto's thyroiditis                                                               
   No                        66      29 508         2.24    1.00                        1.00
   Yes                       28      7489           3.74    1.67 (1.41 to 1.99)\*\*\*   1.91 (1.58 to 2.33)\*\*\*
  Age, year                                                                             
   ≤34                       13      13 649         0.95    1.00                        1.00
   35--49                    31      14 158         2.19    2.30 (1.79 to 2.95)\*\*\*   2.14 (1.67 to 2.75)\*\*\*
   50+                       50      9190           5.44    5.71 (4.51 to 7.23)\*\*\*   4.33 (3.33 to 5.64)\*\*\*
  Sex                                                                                   
   Female                    83      33 763         2.46    1.00                        1.00
   Male                      11      3234           3.40    1.38 (1.08 to 1.72)\*       1.07 (0.84 to 1. 37)
  Comorbidity                                                                           
   Hyperlipidaemia                                                                      
    No                       62      30 792         2.01    1.00                        1.00
    Yes                      32      6205           5.16    2.56 (2.17 to 3.03)\*\*\*   1.39 (1.15 to 1. 68)\*\*\*
   Diabetes                                                                             
    No                       81      34 947         2.32    1.00                        1.00
    Yes                      13      2050           6.34    2.74 (2.17 to 3.44)\*\*\*   1.55 (1.22 to 1.97)\*\*\*
   Liver cirrhosis                                                                      
    No                       93      36 889         2.52    1.00                        1.00
    Yes                      1       110            9.07    3.60 (1.66 to 7.82)\*\*     2.27 (1.07 to 4.85)\*\*\*
   Alcohol-related illness                                                              
    No                       92      36 423         2.53    1.00                        1.00
    Yes                      2       574            3.49    1.38 (0.79 to 2.40)         --
   Hypertension                                                                         
    No                       68      30 822         2.21    1.00                        1.00
    Yes                      26      6175           4.21    1.91 (1.60 to 2.28)\*\*\*   0.68 (0.55 to 1.00)
   COPD                                                                                 
    No                       85      34 669         2.45    1.00                        1.00
    Yes                      9       2328           3.87    1.58 (1.20 to 2.07)\*\*\*   0.92 (0.70 to 1.20)
   Obesity                                                                              
    No                       92      36 011         2.55    1.00                        1.00
    Yes                      2       986            2.03    0.79 (0.46 to 1.38)         --
   Stroke                                                                               
    No                       93      36 784         2.53    1.00                        1.00
    Yes                      1       213            4.69    1.86 (0.85 to 4.03)         --
   CAD                                                                                  
    No                       69      33 530         2.06    1.00                        1.00
    Yes                      25      3468           7.21    3.50 (2.93 to 4.19)\*\*\*   2.04 (1.67 to 2.50)\*\*\*
   Hepatitis B virus                                                                    
    No                       90      35 843         2.51    1.00                        1.00
    Yes                      4       1154           3.47    1.38 (0.93 to 2.05)         --
   Hepatitis C virus                                                                    
    No                       92      36 509         2.52    1.00                        1.00
    Yes                      2       488            4.10    1.63 (0.94 to 2.82)         --
   IBD                                                                                  
    No                       92      36 785         2.50    1.00                        1.00
    Yes                      2       211            9.47    3.79 (2.18 to 6.57)\*\*\*   3.21 (1.87 to 5.52)\*\*\*
   Hyperthyroidism                                                                      
    No                       87      34 335         2.53    1.00                        1.00
    Yes                      7       2662           2.63    1.94 (1.60 to 2.36)\*\*\*   0.77 (0.56 to 1.06)
   Hypothyroidism                                                                       
    No                       88      35 359         2.49    1.00                        1.00
    Yes                      6       1638           3.66    1.47 (1.06 to 2.04)\*       0.76 (0.54 to 1.07)

Crude HR, relative HR.

\*P\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

†Incidence rate, per 1000 person-years.

‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, COPD, CAD, IBD, hyperthyroidism and hypothyroidism.

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease.

[Table 3](#T3){ref-type="table"} presents the comparison of the cholelithiasis incidence densities between patients with and without HT stratified by demographic characteristics and the presence or absence of a comorbidity. The age-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients aged ≥50 years (aHR=2.59, 95% CI 1.33 to 5.03). The sex-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for women (aHR=1.99, 95% CI 1.63 to 2.44). The comorbidity-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients without comorbidities (aHR=2.29, 95% CI 1.77 to 2.95) or with comorbidities (aHR=1.38, 95% CI 1.08 to 1.76).

###### 

Comparison of the cholelithiasis incidence densities between patients with and without Hashimoto's thyroiditis by demographic characteristics and presence or absence of a comorbidity

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables     Hashimoto's thyroiditis   Crude HR (95% CI)   Adjusted HR‡\                                                  
                                                              (95% CI)                                                       
  ------------- ------------------------- ------------------- --------------- ---- ------ ------ --------------------------- ---------------------------
  Age, years                                                                                                                 

   ≤49          33                        22 137              1.49            11   5670   1.94   1.30 (1.04 to 1.63)\*       1.29 (0.57 to 2.92)

   50+          33                        7371                4.48            17   1819   9.35   2.09 (1.56 to 2.80)\*\*\*   2.59 (1.33 to 5.03)\*\*\*

  Sex                                                                                                                        

   Female       58                        26 916              2.15            25   6847   3.65   1.69 (1.41 to 2.03)\*\*\*   1.99 (1.63 to 2.44)\*\*\*

   Male         8                         2592                3.09            3    642    4.67   1.51 (0.86 to 2.66)         1.33 (0.63 to 2.79)

  Comorbidity                                                                                                                

   No           22                        18 054              1.22            7    2491   2.81   2.07 (1.58 to 2.71)\*\*\*   2.29 (1.77 to 2.95)\*\*\*

   Yes          44                        11 454              3.84            21   4998   4.20   1.18 (0.92 to 1.50)         1.38 (1.08 to 1.76)\*\*
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Crude HR, relative HR.

\*P\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

†Incidence rate, per 1000 person-years.

‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.

Compared with those in the non-HT cohort, patients with HT without (aHR=1.95, 95% CI 1.53 to 2.49) and with (aHR=1.94, 95% CI 1.51 to 2.49) thyroxine treatment were associated with a higher risk of cholelithiasis ([table 4](#T4){ref-type="table"}).

###### 

Incidence and HR of cholelithiasis compared between non-HT cohort and patients with HT with and without thyroxine (T4) treatment

  Variables                 n      Event   Person-years   Rate†   Crude HR                    Adjusted HR‡ (95% CI)
  ------------------------- ------ ------- -------------- ------- --------------------------- ---------------------------
  Non-HT controls           5021   66      29 508         2.24    1 (reference)               1 (reference)
  HT without T4 treatment   556    12      3276           3.66    1.64 (1.29 to 2.09)\*\*\*   1.95 (1.53 to 2.49)\*\*\*
  HT with T4 treatment      712    16      4213           3.8     1.70 (1.37 to 2.10)\*\*\*   1.94 (1.51 to 2.49)\*\*\*

Crude HR, relative HR.

\*P\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

†Incidence rate, per 1000 person-years.

‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.

HT, Hashimoto's thyroiditis.

[Table 5](#T5){ref-type="table"} shows the overall incidence of cholecystectomy and estimated HRs according to HT status by Cox proportional hazard regression model. Compared with those in the non-HT cohort, patients with HT had a higher risk of cholecystectomy (aHR=1.28, 95% CI 1.02 to 1.61). Similarly, HT was consistently associated with the risk of cholecystectomy (aHR=1.33, 95% CI 1.05 to 1.69) after we excluded the 171 patients with a history of GD from the HT cohort (data not shown).

###### 

Overall incidence of cholecystectomy (per 1000 person-years) and estimated HRs according to Hashimoto's thyroiditis status by Cox proportional hazard regression model

  Incidence                         Hashimoto's thyroiditis   
  --------------------------------- ------------------------- -----------------------
  Cholecystectomy                                             
  Person-years                      29 678                    7572
  Follow-up time (years), mean±SD   5.91±3.22                 5.98±3.23
  Event, n                          30                        7
  Rate                              1.01                      0.92
  Crude HR (95%  CI)                1 (reference)             0.91 (0.74 to 1.14)
  Adjusted HR (95% CI)†             1 (reference)             1.28 (1.02 to 1.61)\*

\*p\<0.05

Crude HR, relative HR.

†Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.

Discussion {#s4}
==========

We observed that the prevalence of HT was higher in women (90.0%) and in patients older than 35 years (65.5%), with a mean age of 42.7±13.6 years. Furthermore, the age-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients aged ≥50 years, and the sex-specific relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for women ([table 3](#T3){ref-type="table"}). These findings reflect the concerns regarding the survey of cholelithiasis in women aged ≥50 years with HT. Furthermore, the reasons for no relationship between male gender and age \<50 years with increased cholelithiasis incidence in patients with HT might be due to the smaller study populations of men (n=127) and the smaller case number of cholelithiasis (44 of 913), respectively.

Excluding hyperthyroidism and hypothyroidism, our findings were consistent with the literature to demonstrate that the top three common comorbidities associated with HT were hypertension, hyperlipidaemia and CAD ([table 1](#T1){ref-type="table"}).[@R21] Hypothyroidism can lead to atherosclerosis and arterial stiffness through increased production of total and low-density lipoprotein (LDL) cholesterol, increased levels of apolipoprotein B and elevated levels of homocysteine.[@R22] Furthermore, the increase in total and LDL cholesterol and apolipoprotein B is proportional to the severity of hypothyroidism. Furthermore, an autoimmune process and chronic inflammation in HT have been supposed to be directly related to the development of cardiovascular disease.[@R25] HT and GD are generally believed to share a number of common aetiological factors, although they may have different phenotypes of the thyroid functions. It is more frequent for GD to spontaneously evolve to HT, while the development of GD from HT was quite rare.[@R26] Consistent with the literature, approximately 46.6% of patients with HT with a history of hyperthyroidism ever presented the diagnosis of GD in our study.

Age, hyperlipidaemia, diabetes, liver cirrhosis, CAD and IBD remained the independent risk factors for cholelithiasis, as determined in multivariable analysis ([table 2](#T2){ref-type="table"}). The risk of cholelithiasis increased with increasing age because of increased biliary cholesterol secretion, impaired 7-α hydroxylase activity and bile salt synthesis, impaired gallbladder contraction, and increased exposure to lithogenic factors, although pigment stone remains the most common stone type encountered in the elderly population.[@R4] The association between cholelithiasis and hypercholesterolaemia remains controversial; however, a low high-density lipoprotein cholesterol level and hypertriglyceridaemia are associated with an increased risk of stones.[@R4] Diabetes, associated with insulin resistance, can lead to increased cholesterol saturation in the bile and impaired gallbladder motility.[@R29] Liver cirrhosis is associated with the development of black pigment stones because of altered pigment secretion, impaired gallbladder contraction and increased oestrogen levels.[@R4] CAD and cholelithiasis may share a common pathophysiological mechanism of increasing cholesterol deposition in the atherosclerotic plaque and cholesterol saturation in the bile.[@R31] IBD can cause cholesterol stones by reducing bile acid reabsorption in the terminal ileum, and the absorbed bile acid can cause pigment stones by dissolving bilirubin and increasing its absorption in enterohepatic cycling.[@R33] However, a possible surveillance bias was raised because patients with comorbidities are more likely to get diagnosed with incidental cholelithiasis than patients without these morbidities. The inclusion of asymptomatic cholelithiasis in the outcome group could inadvertently tag more indications of abdominal imaging, and therefore lead to unexpected associations between some comorbidities with cholelithiasis.

Our results reveal that HT was closely related to the development of cholelithiasis, after adjustment for age, sex, hyperlipidaemia, diabetes, liver cirrhosis, hypertension, COPD, CAD, IBD, hyperthyroidism and hypothyroidism in the Cox proportional hazards regression. Furthermore, the relative risk of cholelithiasis in the HT cohort was higher than that in the non-HT cohort for patients without or with a comorbidity. In addition, the risk of cholelithiasis in the HT cohort increased with an incremental duration of follow-up after HT diagnosis ([figure 2](#F2){ref-type="fig"}). These findings confirm an increased risk of cholelithiasis after HT diagnosis, although we could not establish the causal relationship between HT and cholelithiasis in this observational study. However, there may be a surveillance bias raised by a more incidental diagnosis on abdominal imaging due to HT as there is no routine screening of asymptomatic cholelithiasis and a vast majority of these non-HT individuals with cholelithiasis may remain undiagnosed. Furthermore, the presence of cholelithiasis may not be noted in the insurance claims data because no treatment was required. However, HT was consistently associated with the risk of cholecystectomy after we assessed the clinically relevant outcome of cholecystectomy to minimise possible misclassification of symptomatic cholelithiasis.

Consistent with the literature, our study demonstrated that HT was related to the development of cholelithiasis, and these findings might be attributed to the sequel of hypothyroidism.[@R15] The possible pathophysiological mechanisms underlying the development of cholelithiasis after HT diagnosis are as follows. First, hypothyroidism reduces liver cholesterol metabolism, resulting in cholesterol supersaturation due to lack of thyroxine.[@R35] Second, decreased bile secretion from the hepatocytes results in bile crystallisation.[@R36] Third, changes in the bile composition and decreased relaxation of the sphincter of Oddi in hypothyroidism delay the flow of bile into the duodenum. Moreover, gallbladder contractility and intestinal motility are impaired in hypothyroidism.[@R36] Finally, in addition to hypothyroidism, HT-associated vasculitis or oxidative stress could predispose to the development of cholelithiasis.[@R39] The use of thyroxine does not seem to ameliorate the increased incidence of cholelithiasis for HT since patients with HT with (aHR=1.94, 95% CI 1.51 to 2.49) and without (aHR=1.95, 95% CI 1.53 to 2.49) thyroxine treatment were similarly associated with a higher risk of cholelithiasis than those in the non-HT cohort and their aHRs were comparable ([table 4](#T4){ref-type="table"}). These findings support that the association between HT and cholelithiasis might not simply be relevant to the thyroid function.

Our study has several strengths. First, this is the first population-based cohort study on the association between HT and cholelithiasis. Additionally, we used a longitudinal database with a 12-year observation period for a large cohort size of 1 000 000 residents to demonstrate the association between HT and the subsequent development of cholelithiasis. Second, the Taiwan NHI programme covers healthcare for more than 99% of the residents of Taiwan under a single-payer system, and all the insurance claims for medical reimbursement have shown a substantial concordance in the literature.[@R41] Therefore, the present findings reveal an association between HT and cholelithiasis based on the real situations of Taiwan with a profoundly large sample size and can represent generalisability in Taiwan. However, more studies are required to clarify the association, which may vary with ethnicity and environment.

Our study also has several limitations. First, the evidence derived from a retrospective cohort study is generally of lower methodological quality than that from randomised trials since the retrospective cohort study is subject to many biases related to the necessary adjustments for confounding factors. Many of these factors could not be ascertained at all from the insurance claims database (eg, postmenopausal hormone use, diet, coffee, alcohol, smoking and so on), and some could only be ascertained partially (eg, obesity instead of body mass index) even though we have used the diagnosis of COPD and alcohol-related illness as replacements for the habits of smoking and alcohol consumption, respectively. Second, we could not validate the diagnosis of HT and cholelithiasis by individually reviewing the medical records. However, the NHI programme is managed by the Taiwanese government, and all insurance claims are audited based on standard diagnostic criteria for medical reimbursement.[@R41] Medical providers are fined and face administrative sanction if the diagnostic coding and claims data are incorrect. Third, the 171 patients with a history of GD before evolving to HT might belong to a heterogeneous autoimmune thyroid disease group, rather than conventionally defined HT, since they often had positive antibodies and chronic inflammatory features in sonography that are difficult to differentiate from HT. However, HT was consistently associated with the risk of cholelithiasis or cholecystectomy even though we have excluded the 171 patients with a history of GD from the HT cohort. Fourth, the association between HT and cholelithiasis might be skewed by surveillance bias since patients with HT would get more opportunities for abdominal imaging studies, or the presence of cholelithiasis was not recorded in the insurance claims data because no treatment was required. However, the association has been supported by the association between cholecystectomy and HT in our study, although asymptomatic cholelithiasis and cholecystectomy might be different entities. Finally, the definite pathophysiology and the causal relationship for the association between HT and cholelithiasis could not be ascertained in this observational study and more studies are required to clarify the relationship. However, the association could not be simply explained by hypothyroidism. HT per se might be associated with the development of cholelithiasis, and was supported by our findings that the association persisted in multivariable Cox proportional hazard regression model after controlling for the confounding factors, including hyperthyroidism and hypothyroidism, Furthermore, with comparable aHRs, patients with HT with and without thyroxine treatment were similarly associated with a higher risk of cholelithiasis than those in the non-HT cohort.

In conclusion, our population-based cohort study demonstrated HT per se was associated with the development of cholelithiasis, particularly in women aged ≥50 years. The risk of cholelithiasis increased with the follow-up time after a diagnosis of HT. Surveys and health education on cholelithiasis in women aged ≥50 years with HT should be considered by clinicians and further prospective research should be done on this topic. The aforementioned association has been supported by the association between cholecystectomy and HT. However, inability to obtain information on several potential confounding factors and misclassification of important covariates are major limitations of the study.
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